2023
DOI: 10.1016/j.clindermatol.2023.07.003
|View full text |Cite
|
Sign up to set email alerts
|

Annular neutrophilic dermatoses

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 107 publications
0
0
0
Order By: Relevance
“…The role of this inflammasome in mediating cutaneous immunity is also apparent from the enhanced sensitivity of mice with keratinocyte-selective deletion of Nlrp10 to contact dermatitis [116]. Drugs targeting inflammasome activation or outcome, such as colchicine and Anakinra, are used to treat several inflammatory skin diseases, including neutrophilic dermatoses and hidradenitis suppurativa [117,118]. Various clinical trials targeting IL-1 family cytokines to ameliorate dermatological conditions have been initiated and are reviewed elsewhere [119].…”
Section: Pyroptosismentioning
confidence: 99%
“…The role of this inflammasome in mediating cutaneous immunity is also apparent from the enhanced sensitivity of mice with keratinocyte-selective deletion of Nlrp10 to contact dermatitis [116]. Drugs targeting inflammasome activation or outcome, such as colchicine and Anakinra, are used to treat several inflammatory skin diseases, including neutrophilic dermatoses and hidradenitis suppurativa [117,118]. Various clinical trials targeting IL-1 family cytokines to ameliorate dermatological conditions have been initiated and are reviewed elsewhere [119].…”
Section: Pyroptosismentioning
confidence: 99%